In a March 24 news release, the pharmacy company said it will close the 692,000-square-foot drugmaking facility by July 9, just 14 months after its opening.
Laid-off workers will be offered severance packages, job placement support and some other benefits, Novartis said.
Novartis opened the plant to produce its spinal muscular atrophy gene therapy drug Zolgensma but said it decided its other sister plants can produce it.
“We will now focus on meeting the needs of patients through our Libertyville, Ill., and Durham, N.C., sites, where we will continue to invest in next-generation processes,” Novartis told The Longmont Times-Call.
More articles on pharmacy:
Mississippi Medicaid officials investigate Centene’s pharmacy payments
Regeneron says its COVID-19 antibody cocktail reduces hospitalization, death risk by 70%
Pfizer testing oral antiviral COVID-19 drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
